Answers are grounded in this paper and cite their sources.
With the implementation of the DCISionRT (PreludeDx, Laguna Hills, CA) 7-gene biosignature into clinical practice, radiation oncologists are now able to provide patients with DCIS more personalized treatment recommendations regarding pursuing adjuvant radiation treatment or omitting, as the DCISionRT clinicogenomic biosignature is both prognostic for recurrence risk after breast-conserving surgery as well as predictive for benefit of radiation treatment.
No takes yet. Share an insight, caveat, or question.
Amishi Bajaj (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: